We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long-term follow-up of adalimumab monotherapy for rheumatoid arthritis in Japanese patients: a report of six cases.
- Authors
Ichinose, Kunihiro; Origuchi, Tomoki; Kawashiri, Shin-ya; Iwamoto, Naoki; Fujikawa, Keita; Aramaki, Toshiyuki; Kamachi, Makoto; Arima, Kazuhiko; Tamai, Mami; Nakamura, Hideki; Ida, Hiroaki; Kawakami, Atsushi; Eguchi, Katsumi
- Abstract
We present six cases of patients with Japanese rheumatoid arthritis (RA) treated with a tumor necrosis factor (TNF)-alpha blocking agent, adalimumab as monotherapy for 220 weeks. All six patients were women, and the median age was 54.0 ± 7.07 years old. The median duration of the disease was 7.43 ± 11.1 years, and the median disease activity score (DAS28-CRP) was 5.35 ± 0.69. Three of six patients were able to continue to receive this treatment for 220 weeks successfully, and the DAS28-CRP decreased to 1.89 ± 0.75. Two patients withdrew because of lack of efficacy, and one patient withdrew because of adverse events (non-Hodgkin lymphoma). Adalimumab resulted in a sustained clinical response in RA patients during 220-week follow-up.
- Subjects
JAPAN; RHEUMATOID arthritis treatment; TUMOR necrosis factors; BLOCKING antibodies; ADALIMUMAB
- Publication
Rheumatology International, 2012, Vol 32, Issue 2, p483
- ISSN
0172-8172
- Publication type
Article
- DOI
10.1007/s00296-010-1770-1